Last reviewed · How we verify

Tranexamic Acid Irrigation

University of Wisconsin, Madison · FDA-approved active Small molecule

Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing bleeding during surgical procedures when applied as a local irrigation.

Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing bleeding during surgical procedures when applied as a local irrigation. Used for Reduction of perioperative bleeding in orthopedic and general surgical procedures.

At a glance

Generic nameTranexamic Acid Irrigation
Also known asTXA
SponsorUniversity of Wisconsin, Madison
Drug classAntifibrinolytic agent
TargetPlasminogen / Plasmin
ModalitySmall molecule
Therapeutic areaSurgery / Hemostasis
PhaseFDA-approved

Mechanism of action

Tranexamic acid is an antifibrinolytic agent that competitively inhibits the conversion of plasminogen to plasmin, preventing the breakdown of fibrin clots. When used as a surgical irrigation solution, it acts locally at the surgical site to stabilize clot formation and reduce perioperative blood loss. This mechanism is particularly useful in orthopedic and other surgical procedures where local hemostasis is critical.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results